-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] An "Announcement on the Company's Proposed Asset Disposal" issued by Northeast Pharmaceuticals on the evening of August 14 attracted industry attentio.
According to the announcement, according to business needs, the company plans to dispose of two sets of real estate located at N.
37 Yuzhong West Road, Xicheng District, Beijing, with an area of 83 square meters and 64 square meters respectivel.
As of July 31, 2022, the original value of the two property assets was 85236534 billion yuan and the net value was 5038088 million yua.
Northeast Pharmaceuticals stated that because this asset disposal is planned to be carried out in the same way as public online sale and online auction, the transferee will be publicly solicited, and the transaction counterparty has not yet been determine.
For the purpose of the sale of the property, Northeast Pharmaceuticals stated that it will help the company to tap silent assets, revitalize inefficient assets, improve the efficiency of asset use, and help the development of the main busines.
According to the data, Northeast Pharmaceuticals is a pharmaceutical manufacturing enterprise covering the entire industrial chain of pharmaceutical R&D, production and sales, and has the advantage of "API + preparation" integratio.
The 2021 annual report shows that the company's net profit attributable to about 903 million yuan, a year-on-year increase of 7093.
In the first quarter of 2022, the company's performance continued to grow, with attributable net profit of about 633 million yuan, a year-on-year increase of 765.
In fact, it is not only Northeast Pharmaceuticals that pharmaceutical companies have opened the "selling and selling" model for the development of their main busines.
In recent years, pharmaceutical companies selling houses also include Kangzhi Pharmaceutical, Hisun Pharmaceutical, and Foci Pharmaceutica.
Among them, in December 2021 alone, a number of pharmaceutical companies have announced the sale of house.
For example, Hisun Pharmaceutical issued an announcement stating that it will list 5 apartments in Jiaojiang District, Taizhou City for sale
According to the announcement of Foci Pharmaceuticals, in order to effectively revitalize the company's existing assets, focus on the main business of pharmaceuticals, and reduce the company's financial pressure, the company plans to transfer two lands located in Anning District, Lanzhou City to the controlling shareholder Foci Pharmaceutical Group at a price of 103 million yua.
Kangzhi Pharmaceutical announced that the company plans to sell a property located in Haikou City with a total area of 88035 square meters, with an appraised value of 417 million yua.
It is worth mentioning that in 2021, Kangzhi Pharmaceutical has sold houses for many time.
As early as March 2021, Hisun Pharmaceutical announced that it would sell its idle properties in Beijing, Shanghai, Hangzhou, and Jiaojiang at a price of 92616 million yua.
Then in June, Hisun Pharmaceutical (Hangzhou), a subsidiary of Hisun Pharmaceutical Holdings, announced that the new office building in Lushan New District, Fuyang, Hangzhou was ready to be sold at the first listing price of 290 million yuan, and in September the property was sold to Jinhao Real Estat.
In addition, the company also plans to re-list the remaining 5 apartments in Junyue Building in Jiaojiang Distric.
.
.
.
. From the perspective of the industry, in recent years, the pharmaceutical industry has introduced a series of policies such as the consistency evaluation of generic drugs, centralized procurement, medical insurance cost control, and key monitoring of auxiliary drug.
The profit margins of pharmaceutical companies have been squeezed and the pressure has double.
, the entire market reshuffle to speed u.
It is a general trend for pharmaceutical companies to sell assets, with the purpose of revitalizing assets, improving performance, and focusing on the development of their main busines.
It is worth mentioning that although there are cases of pharmaceutical companies selling houses and technologies to solve their difficulties, the way of selling assets is not sustainabl.
Competitiveness in order to gain a firm foothold in the marke.
From the perspective of industry development trends, the overall concentration of the pharmaceutical industry will also be further improved in the futur.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
According to the announcement, according to business needs, the company plans to dispose of two sets of real estate located at N.
37 Yuzhong West Road, Xicheng District, Beijing, with an area of 83 square meters and 64 square meters respectivel.
As of July 31, 2022, the original value of the two property assets was 85236534 billion yuan and the net value was 5038088 million yua.
Northeast Pharmaceuticals stated that because this asset disposal is planned to be carried out in the same way as public online sale and online auction, the transferee will be publicly solicited, and the transaction counterparty has not yet been determine.
For the purpose of the sale of the property, Northeast Pharmaceuticals stated that it will help the company to tap silent assets, revitalize inefficient assets, improve the efficiency of asset use, and help the development of the main busines.
According to the data, Northeast Pharmaceuticals is a pharmaceutical manufacturing enterprise covering the entire industrial chain of pharmaceutical R&D, production and sales, and has the advantage of "API + preparation" integratio.
The 2021 annual report shows that the company's net profit attributable to about 903 million yuan, a year-on-year increase of 7093.
In the first quarter of 2022, the company's performance continued to grow, with attributable net profit of about 633 million yuan, a year-on-year increase of 765.
In fact, it is not only Northeast Pharmaceuticals that pharmaceutical companies have opened the "selling and selling" model for the development of their main busines.
In recent years, pharmaceutical companies selling houses also include Kangzhi Pharmaceutical, Hisun Pharmaceutical, and Foci Pharmaceutica.
Among them, in December 2021 alone, a number of pharmaceutical companies have announced the sale of house.
For example, Hisun Pharmaceutical issued an announcement stating that it will list 5 apartments in Jiaojiang District, Taizhou City for sale
According to the announcement of Foci Pharmaceuticals, in order to effectively revitalize the company's existing assets, focus on the main business of pharmaceuticals, and reduce the company's financial pressure, the company plans to transfer two lands located in Anning District, Lanzhou City to the controlling shareholder Foci Pharmaceutical Group at a price of 103 million yua.
Kangzhi Pharmaceutical announced that the company plans to sell a property located in Haikou City with a total area of 88035 square meters, with an appraised value of 417 million yua.
It is worth mentioning that in 2021, Kangzhi Pharmaceutical has sold houses for many time.
As early as March 2021, Hisun Pharmaceutical announced that it would sell its idle properties in Beijing, Shanghai, Hangzhou, and Jiaojiang at a price of 92616 million yua.
Then in June, Hisun Pharmaceutical (Hangzhou), a subsidiary of Hisun Pharmaceutical Holdings, announced that the new office building in Lushan New District, Fuyang, Hangzhou was ready to be sold at the first listing price of 290 million yuan, and in September the property was sold to Jinhao Real Estat.
In addition, the company also plans to re-list the remaining 5 apartments in Junyue Building in Jiaojiang Distric.
.
.
.
. From the perspective of the industry, in recent years, the pharmaceutical industry has introduced a series of policies such as the consistency evaluation of generic drugs, centralized procurement, medical insurance cost control, and key monitoring of auxiliary drug.
The profit margins of pharmaceutical companies have been squeezed and the pressure has double.
, the entire market reshuffle to speed u.
It is a general trend for pharmaceutical companies to sell assets, with the purpose of revitalizing assets, improving performance, and focusing on the development of their main busines.
It is worth mentioning that although there are cases of pharmaceutical companies selling houses and technologies to solve their difficulties, the way of selling assets is not sustainabl.
Competitiveness in order to gain a firm foothold in the marke.
From the perspective of industry development trends, the overall concentration of the pharmaceutical industry will also be further improved in the futur.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
